Clinical Trial Details


Research Study Summary

A Phase III multi-center prospective randomized, parallel-group, placebo-controlled, double-blind, clinical evaluation of NX-1207 for the treatment of BPH (Benign Prostatic Hyperplasia, or Enlarged Prostate)


The purpose of this study is to evaluate the efficacy and safety of NX-1207 and to see if it could be useful for men with BPH. The study treatment will consist of either an injection of NX-1207 or of a placebo into the prostate. If you end up receiving the placebo, you will be offered the chance to receive NX-1207 at the end of the study. The study will last for 12 months.


  • Male ≥ 45 years of age
  • History of BPH for at least 1 year


  • Acute or chronic Prostatitis in the past 12 months
  • Urinary Tract Infections more than once in the past 12 months
  • Previous surgical or invasive prostate treatments such as TURP, TUMT, and TUNA, laser or any minimally invasive treatments.
  • History of urinary retention in the past 12 months
  • Prostate or bladder cancer
  • PSA ≥ 10

To Learn more

CW ID: 178190
Date Last Changed: May 2, 2014

Clinical Trial Snapshot

45 and up
Overall Status
Facility Type


Debbie Johnson, CCRC, Director of Research
First Urology, PSC
101 Hospital Blvd.
Jeffersonville, IN 47130
Phone: (812) 206-8161
Fax: (812) 288-2612

View Map

Research Center Information:

First Urology, PSC

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.